Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
Author:
Publisher
Springer Science and Business Media LLC
Link
http://link.springer.com/content/pdf/10.1186/s13059-014-0461-8.pdf
Reference88 articles.
1. Lopez-Otin C, Hunter T: The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer. 2010, 10: 278-292.
2. Brognard J, Hunter T: Protein kinase signaling networks in cancer. Curr Opin Genet Dev. 2011, 21: 4-11. 10.1016/j.gde.2010.10.012.
3. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW: Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012, 12: 513-526. 10.1038/nrc3317.
4. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013, 122: 872-884. 10.1182/blood-2013-05-501569.
5. Perrotti D, Jamieson C, Goldman J, Skorski T: Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010, 120: 2254-2264. 10.1172/JCI41246.
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08
2. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22
3. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase;Frontiers in Oncology;2024-07-01
4. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain;Blood;2024-05-23
5. Ponatinib‐review of historical development, current status, and future research;American Journal of Hematology;2024-05-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3